RBC Capital maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) and lowered its price target to $118.00 (from $125.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change Hot Comments

Gilead Sciences (GILD) Commentary Does Little to Quell Fears But Stock Undervalued - CowenFebruary 4, 2015 9:08 AM Gilead Sciences (GILD) PT Trimmed to $116 at Piper Jaffray as Guidance was a LetdownFebruary 4, 2015 8:54 AM Goldman Sachs Lowers Its Price Target on Gilead (GILD) to $85 February 4, 2015 8:26 AM Gilead Sciences (GILD) Estimates Trimmed at Needham & Company Post Q4; 'Buy' MaintainedFebruary 4, 2015 8:16 AM Gilead Sciences (GILD) PT Trimmed to $141 at Nomura Posts Q4February 4, 2015 7:40 AM Baird 'Incrementally Negative' on Gilead (GILD) Following CallFebruary 4, 2015 7:11 AM Gilead Sciences (GILD) Tops Q4 EPS by 22c; Approves Dividend Program, $15B BuybackFebruary 3, 2015 4:06 PM